Explanipedia

Persistent B Cell Depletion After Rituximab for Autoimmune and Glomerular Diseases: A Case Series Open

Orhan Efe, Gabriel Sauvage, Anushya Jeyabalan, Ayman Al Jurdi, Harish Seethapathy , et al. · 2025

Protracted COVID-19 pneumonia in B-cell-depleted patients Open

Orhan Efe, Gabriel Sauvage, James Chung, Anushya Jeyabalan, Ayman Al Jurdi , et al. · 2024

Combination Induction Immunosuppression With Rituximab, Cyclophosphamide, and Prednisone for Fibrillary Glomerulonephritis Open

Gabriel Sauvage, Reza Zonozi, Harish Seethapathy, Orhan Efe, Anushya Jeyabalan , et al. · 2024

Real-World Experience With Avacopan in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis Open

Reza Zonozi, Faten Aqeel, Dustin Le, Frank B. Cortazar, Jugal Thaker , et al. · 2024

Bronchitis during long-term treatment with rituximab for ANCA-associated vasculitis: a retrospective cohort study Open

Reza Zonozi, Anushya Jeyabalan, Orhan Efe, Gabriel Sauvage, Katherine Cosgrove , et al. · 2023

Background Pulmonary complications from B cell depletion with rituximab remain with limited description in the literature. Our objective is to describe the frequency and risk factors for development of bronchitis in patients receiving prol…

Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan Open

Faten Aqeel, Reza Zonozi, Anushya Jeyabalan, Gabriel Sauvage, John L. Niles , et al. · 2023

Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan Open

Frank B. Cortazar, John L. Niles, David Jayne, Peter A. Merkel, Annette Bruchfeld , et al. · 2023

POS-444 EFFECT OF AVACOPAN, A SELECTIVE C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS Open

David Jayne, Peter A. Merkel, Pirow Bekker, Annette Bruchfeld, Duvuru Geetha , et al. · 2022

Patients with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis and renal disease have a poor prognosis. The effect of avacopan, an oral C5a receptor inhibitor, on renal function is described.

Association of renal transplantation with reduced risk of myocardial infarction and ischemic stroke in ANCA-associated vasculitis: An observational cohort study Open

Claire Cook, April Jorge, Xiaoqing Fu, John L. Niles, Anushya Jeyabalan , et al. · 2021

Inflammatory vaginitis in women on long-term rituximab treatment for autoimmune disorders Open

Laura J. Yockey, Sarah Dowst, Reza Zonozi, Noah Huizenga, Patrick J. Murphy , et al. · 2021

Eculizumab and Complement Activation in Anti−glomerular Basement Membrane Disease Open

Pravarut Nithagon, Frank B. Cortazar, Sujal I. Shah, Astrid Weins, Karen Laliberte , et al. · 2021

Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up Open

Reza Zonozi, Karen Laliberte, Noah Huizenga, Jillian K. Rosenthal, Anushya Jeyabalan , et al. · 2021

Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab Open

Orhan Efe, Lipika Goyal, Aralee Galway, Andrew X. Zhu, John L. Niles , et al. · 2021

Thrombotic microangiopathies (TMAs) are life-threatening clinical syndromes due to dysregulation of the complement and coagulation cascades.1 When a precipitant to endothelial injury persists (e.g., from infection, drug, autoimmunity, mali…

COVID-19 Recovery Without B Cells or Antibodies in Patients Receiving Rituximab for Autoimmune Disease. Open

Reza Zonozi, Noah Huizenga, Richelle C. Charles, Anushya Jeyabalan, John L. Niles · 2021

No Abstract.

Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Open

Peter A. Merkel, John L. Niles, Richard Jimenez, Robert Spiera, Brad H. Rovin , et al. · 2020

Objective This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis in addition to standard‐of‐care (SOC) treat…

Incidence, Clinical Features, and Outcomes of Late‐Onset Neutropenia From Rituximab for Autoimmune Disease Open

Reza Zonozi, Zachary S. Wallace, Karen Laliberte, Noah Huizenga, Jillian Rosenthal , et al. · 2020

Objective Late‐onset neutropenia (LON) is an underrecognized complication of rituximab treatment. We undertook this study to describe its incidence, risk factors, clinical features, management, and recurrence. Methods We conducted a single…

Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis Open

Peter A. Merkel, John L. Niles, Lester E. Mertz, Patricia B. Lehane, Pooneh Pordeli , et al. · 2020

Objective The present study was undertaken to conduct a phase IV, open‐label, prospective study to characterize the long‐term safety of rituximab in a 4‐year observational registry of adult patients with granulomatosis with polyangiitis (G…

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series Open

Frank B. Cortazar, David E. Leaf, Charles Owens, Karen Laliberte, William F. Pendergraft , et al. · 2020

BACKGROUND: Membranous nephropathy is a common cause of the nephrotic syndrome. Treatment with standard regimens fails to induce complete remission in most patients. We evaluated the efficacy of combination therapy with rituximab, low-dose…

Treatment of Aggressive Antineutrophil Cytoplasmic Antibody–Associated Vasculitis With Eculizumab Open

Noah Huizenga, Reza Zonozi, Jillian Rosenthal, Karen Laliberte, John L. Niles , et al. · 2019

Phospholipase A2 receptor–associated membranous nephropathy in a patient with IgG4-related disease Open

Saif A. Muhsin, Ricard Masia, R. Neal Smith, Zachary S. Wallace, Cory A. Perugino , et al. · 2019

Rationale: IgG4-related disease (IgG4-RD) is a multiorgan disease of unestablished prevalence that is characterized histopathologically by a dense lymphoplasmacytic infiltrate enriched with IgG4-expressing plasma cells and associated with …

364. LATE-ONSET NEUTROPENIA IN PATIENTS UNDERGOING RITUXIMAB-INDUCED CONTINUOUS B CELL DEPLETION FOR AUTOIMMUNE DISEASE: DATA FROM A 738 PATIENT COHORT AND APPROACH TO MANAGEMENT Open

Reza Zonozi, Karen Laliberte, Jillian Rosenthal, Noah Huizenga, Frank B. Cortazar , et al. · 2019

327. LONG-TERM SAFETY OF RITUXIMAB IN GRANULOMATOSIS WITH POLYANGIITIS OR MICROSCOPIC POLYANGIITIS: RESULTS OF THE FOUR-YEAR RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS REGISTRY Open

John L. Niles, Peter A. Merkel, Lester E. Mertz, Patricia B. Lehane, Pooneh Pordeli , et al. · 2019

Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome Open

Frank B. Cortazar, Jillian Rosenthal, Karen Laliberte, John L. Niles · 2018

Continuous B-cell depletion is a therapeutic option in the management of complicated nephrotic syndrome. Additional studies are needed to clarify the utility of this strategy.

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis Open

Frank B. Cortazar, Saif A. Muhsin, William F. Pendergraft, Zachary S. Wallace, Colleen Dunbar , et al. · 2017

Subglottic Stenosis in Granulomatosis With Polyangiitis: The Role of Laryngotracheal Resection Open

Christina L. Costantino, John L. Niles, Cameron D. Wright, Douglas J. Mathisen, Ashok Muniappan · 2017

THU0301 Safety following initiation of rituximab in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA): interim analysis of the rituximab in anca-associated vasculitis registry (RAVER) Open

John L. Niles, NancyB. Allen, Joel A. Block, CL Koening, C. Langford , et al. · 2017

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series Open

Frank B. Cortazar, David E. Leaf, Charles Owens, Karen Laliberte, William F. Pendergraft , et al. · 2017

Treatment of idiopathic membranous nephropathy with RCP resulted in high rates of complete remission. Larger studies evaluating this regimen are warranted.

Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Open

Frank B. Cortazar, William F. Pendergraft, Julia Wenger, Charles Owens, Karen Laliberte , et al. · 2016

Objective To evaluate the effect of rituximab on pathogenic autoantibodies and total Ig levels, and to identify serious adverse events in patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) treated with con…

John L. Niles YOU? Author Swipe